Several preclinical studies have demonstrated strong anti-tumor activity of GITR stimulation using either agonist antibodies (Abs) or multimeric GITRLs as monotherapy or in combination with other types of immunotherapy, including vaccines and immune checkpoint inhibitors (ICI), against multiple syngeneic tumor models. The gene discussed is TNFRSF18; the disease is neoplasm.